Cellular and molecular basis of preferential metastasis of breast cancer to bone

Journal of Orthopaedic Science

Volumn 5, Issue 1, 2000, Pages 75-81

  Yoneda, Toshiyuki ^a  

^a OSAKA UNIVERSITY   (Japan)

Author keywords

Bisphosphonate; Bone metastasis; Osteoclastic bone resorption; Parathyroid hormone related protein

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; INTEGRIN; LAMININ; MATRIX METALLOPROTEINASE; PARATHYROID HORMONE RELATED PROTEIN; UVOMORULIN; VASCULAR CELL ADHESION MOLECULE 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; BONE METASTASIS; BREAST CANCER; CANCER MORTALITY; CARCINOGENESIS; CONFERENCE PAPER; CYTOLOGY; HUMAN; HUMAN CELL; MOLECULAR BIOLOGY; MORBIDITY; NONHUMAN; OSTEOLYSIS; TISSUE SPECIFICITY;

EID: 0034056341     PISSN: 09492658     EISSN: None     Source Type: Journal    
DOI: 10.1007/s007760050012     Document Type: Conference Paper

References (48)

1. Arguello F, Baggs RB, Frantz CN. A murine model of experimental metastasis to bone and bone marrow. Cancer Res 1988;48:6876-81.
2. Benaud C, Dickson RB, Thompson EW. Roles of the matrix metalloproteinases in mammary gland development and cancer. Breast Cancer Res Treat 1998;50:97-116.
3. Boyce BF, Aufdemorte TB, Garrett IR, et al. Effects of interleukin-1 on bone turnover in normal mice. Endocrinology 1989;125:1142-50.
4. Boyde A, Maconnachie E, Reid SA, et al. Scanning electron microscopy in bone pathology: review of methods. Potential and applications. Scanning Electron Microsc 1986;4:1537-54.
5. Bundred NJ, Walker RA, Ratcliffe WA, et al. Parathyroid hormone related protein and skeletal morbidity in breast cancer. Eur J Cancer 1992;28:690-2.
6. Coleman RE, Rubens RD. The clinical course of bone metastases from breast cancer. Br J Cancer 1987;55:61-6.
7. Diel IJ, Solomayer EF, Costa S, et al. Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med 1998;339:357-63.
8. Fidler IJ. Critical factors in the biology of human cancer metastasis. Cancer Res 1990;50:6130-8.
9. Fidler IJ. Modulation of the organ microenvironment for treatment of cancer metastasis. J Natl Cancer Inst 1995;87:1588-92.
10. rd ed. New York: The Parthenon Publishing Group; 1997:11-180.
11. Guise TA, Yin JJ, Taylor SD, et al. Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis. J Clin Invest 1996;98: 1544-9.
12. Hauschka PV, Mavrakos AE, Iafrati MD, et al. Growth factors in bone matrix. Isolation of multiple types by affinity chromatography on heparin-sepharose. J Biol Chem 1986;261:12665-74.
13. Hiraga T, Nakajima T, Ozawa H. Bone resorption induced by a metastatic human melanoma cell line. Bone 1995;16:349-56.
14. Hirshberg A, Leibovich P, Horowitz I, et al. Metastatic tumors to postextraction sites. J Oral Maxillofac Surg 1993;51:1334-7.
15. Hortobagyi GN, Therault RL, Porter L, et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. N Engl J Med 1996;335:1785-91.
16. Kohno N, Kitazawa S, Fukase M, et al. The expression of parathyroid hormone-related protein in human breast cancer with skeletal metastases. Surgery Today 1994;24 215-20.
17. Liapis H, Crouch EC, Grosso LE, et al. Expression of parathyroid-like protein in normal, proliferative and neoplastic human breast tissue. Am J Pathol 1993;143:1169-78.
18. Liotta LA. Cancer cell invasion and metastasis. Sci Amer 1992; 266:2 54-63.
19. Mbalaviele G, Dunstan CR, Sasaki A, et al. E-cadherin expression in human breast cancer cells suppresses the development of osteolytic bone metastases in an experimental metastasis model. Cancer Res 1996;56:4063-70.
20. Michigami T, Dalla SL, Mundy GR, et al. Interactions of myeloma cells with bone marrow stromal cells via α4β1 integrin-VCAM-1 is required for the development of osteolysis. J Bone Miner Res 1997;12:128.
21. Michigami T, Nomizu M, Yamada Y, et al. Growth and dissemination of a newly-established murine B-cell lymphoma cell line is inhibited by multimeric YIGSR peptide. Clin Exp Metastasis 1998;16:645-54.
22. Mundy GR, DeMartino S, Rowe DW. Collagen and collagen fragments are chemotactic for tumor cells. J Clin Invest 1981;68:1102-5.
23. Mundy GR, Yoneda T. Facilitation and suppression of bone metastasis. Clin Orthop Relat Res 1995;312:34-44.
24. Mundy GR, Yoneda T. Bisphosphonates as anticancer drugs. N Engl J Med 1998;339:398-400.
25. Nakai M, Mundy GR, Williams PJ, et al. A synthetic antagonist to laminin inhibits the formation of osteolytic metastases by human melanoma cells in nude mice. Cancer Res 1992;52:5395-9.
26. Oka H, Shiozaki H, Kobayashi K, et al. Expression of E-cadherin cell adhesion molecules in human breast cancer tissues and its relationship to metastasis. Cancer Res 1993;53:1696-701.
27. Orr FW, Varani J, Gondek MD, et al. Chemotactic response of tumor cells to products of resorbing bone. Science 1979:203:176-9.
28. Orr FW, Sanchez-Sweatman OH, Kostenuik P, et al. Tumor-bone interactions in skeletal metastasis. Clin Orthop Relat Res 1995;312 19-33.
29. Oyajobi BO, Traianedes K, Yoneda T, et al. Expression of Rank ligand (RANKL) by myeloma cells requires binding to bone marrow stromal cells via α4β1-VACAM-1 interactions. Bone 1998;23:S180.
30. Paget S. The distribution of secondary growths in cancer of the breast. Lancet 1989;I:571-3.
31. Pfeilschifter J, Mundy GR. Modulation of transforming growth factor beta activity in bone cultures by osteotropic hormones. Proc Natl Acad Sci USA 1987;84:2024-28.
32. Powell GJ, Southby J, Danks JA, et al. Localization of parathyroid hormone-related protein in breast cancer metastases: increased incidence in bone compared with other sites. Cancer Res 1991;51:3059-61.
33. Rusciano D, Burger MM. Why do cancer cells metastasize into particular organs? Bio-essays 1992;14 185-193.
34. Sasaki A, Williams P, Mundy GR, et al. Osteolysis and tumor growth are enhanced in sites of increased bone turnover in vivo. J Bone Miner Res 1994;9:5294.
35. Sasaki A, Boyce BF, Story B, et al. Bisphosphonate risedronate reduces metastalic human breast cancer burden in bone in nude mice. Cancer Res 1995;55:3551-7.
36. Sasaki A, Yoneda T, Terakado N, et al. Experimental bone metastasis model of the oral and maxillofacial region. Anticancer Res 1998;18:1579-84.
37. Schajowicz F, Velan O, Araujo ES, et al. Metastases of carcinoma in the Pagetic bone. A report of two cases. Clin Orthop Rel Res 1988;228:290-6.
38. Shipman CM, Croucher PI, Russell RGG, et al. The bisphosphonate incadronate (YM175) causes apoptosis of human myeloma cells in vitro by inhibiting the mevalonate pathway. Cancer Res 1998;58:5294-7.
39. Sommers CL, Thompson EW, Torri JA, et al. Cell adhesion molecule uvomoruhn expression in human breast cancer cell lines: relationship to morphology and invasive capacities. Cell Growth Diff 1991;2:365-71.
40. Takeichi M. Cadherins in cancer: implications for invasion and metastasis Curr Opin Cell Biol 1993;5:806-11.
41. Vargas SJ, Gillespie MT, Powell GJ, et al. Localization of parathyroid hormone-related protein mRNA expression in metastatic lesions by in situ hybridization. J Bone Miner Res 1992;7:971-80.
42. Walther HE. Krebsmetastasen. Basel: Bens Schwabe Verlag: 1948.
43. Yin JJ, Selander K, Chirgurin JM, et al. TGFβ signaling blockade inhibits PTH-rP secretion by breast cancer cells and bone metastasis development. J Clin Invest 1999;103:197-206.
44. Yoneda T, Sasaki A, Mundy GR. Osteolytic bone disease in breast cancer. Breast Cancer Res Treat 1994;32:73-84.
45. Yoneda T, Williams P, Dunstan C, et al. Growth of metastatic cancer cells in bone is enhanced by bone-derived insulin-like growth factors (IGFs). J Bone Miner Res 1995;10:S269.
46. Yoneda T, Sasaki A, Dunstan C, et al. Inhibition of osteolytic bone metastasis of breast cancer by combined treatment with the bisphosphonate ibandronate and tissue inhibitor of the matrix metalloproteinase-2. J Clin Invest 1997a;99:2509-17.
47. Yoneda T. Arterial microvascularization and breast cancer colonization in bone. Histol Histopathol 1997b;12:1145-9.
48. Yoneda T. Cellular and molecular mechanisms of breast and prostate cancer metastasis to bone. Eur J Cancer 1998;34:240-5.